September 8, 2017 9:33pm
As I had stated, “Share pricing premiums are thinning and the cell and gene therapies are still speculative and slippery.”
Word of the day: eight (8) companies closed FLAT, which most would rather be than a splat
Out and about: Verastem (VSTM) continues its sprint; but, it will come at a price tag of …
Pre-open indications: 5 hits and 1 miss (SGMO)
It’s called premium content for a reason … I define insight from a real-time perspective discussing equity share pricing, attractiveness and support levels as stock pricing changes by the hour … if not the minute!
A key question facing investors: what is the value of reporting the truth in this sector?
If you had been right as many times as I have been in these many months of 2017 as a SUBSCRIBER you would know … who and when to get in and out or get back in again!
I answer one question, in which company should investors commit and keep their money.
Friday’s results have implications to Monday’s sector activity as a daily report may say little or a lot and it serves as insurance that all indications are being examined and evaluated!
Henry’omics:
From the pre-open’s investor’s newsletter “… long or gone over this weekend? Share pricing premiums are thinning after the KITE, SGMO, NVS and VSTM upsides. My concern is that most share pricing has already been anointed, engendered by acquisition, FDA approvals and trial results but has been limited to the few, the cell and gene therapies are still speculative and slippery.”
- As I had speculated, “What’s sticking to these walls … if *you had read last night’s newsletter; you’d be able to define today’s scenario!”
Cell, stem and gene therapy companies moved from the opening upside to a barely positive close.
Feeling the gain was: CLLS (+$1.56) who was slammed for the past two days which also included FCSC (+$0.40) which hasn’t seen many up sessions recently; RGNX, STML, VSTM and even XON.
Getting slammed was: BLUE (-$4.40), ONCE (-$3.19), MDXG (-$1.27), JUNO (-$0.76) and SGMO (-$0.15) – the uppers of yesterday and BLCM.
Of the mid-tier stem cell companies; a number were up: ADVM, ISCO, BLFS, and VTGN - after a depreciating offering and BCLI.
Getting dumped in the relationship with sentiment was: a consistent dud – PSTI.
Flat and not a splat: AXGN, NWBO, CAPR and IMUC- usual losers,
FATE (-$0.07) took a hit after being up yesterday along with KITE (-$0.27), MESO (-$0.27), ONCE 9-$3.19) and a usual suspect – CUR.
My customary target were actually up: BSTG with serious terminal death legal issue hanging over its head and CYTX
AST was flat after being down again -$0.05 after the previous day’s -$0.025 and BTX was up +$0.01 following a flat after the previous day’s up +$0.02 - both NEED to raise capital to keep the trials – on-going!
Under estimated companies: VCEL closed flat after Thursday’s up +$0.15 after being flat at $4.30 with approved products and HSGX was up again +$0.03 following another positive close of +$0.08 after the previous day’s -$0.05 with a P3 milestone.
I have been TELLING you for MONTHS … to watch the patterns!
Pre-open indications: 5 hits and 1 miss:
- Athersys (ATHX) closed up +$0.02 – hit;
- bluebird bio (BLUE) closed down -$4.40 – hit;
- Histogenics (HSGX) closed up +$0.03 – hit;
- Juno Therapeutics (JUNO) closed down -$0.76 – hit;
- Sangamo Therapeutics (SGMO) closed down -$0.15 – miss;
- Verastem (VSTM) closed up +$0.35 – hit;
The advance/decline line scenario of 43 SCGT & RT covered companies:
· The first hour was positive with an A/DL of 23/16 and 4 flat;
· The mid-day was positive with an A/DL of 23/15 and 5 flat;
· The close was positive with an A/DL of 19/16 and 8 flats ;
Out and about:
Verastem (VSTM) continues its sprint; but, it will come at a price tag of … $22 M and royalties to Infinity Pharmaceuticals (INFI) if approved from which it had been acquired. A small price from a $275 M investment by Abbvie (ABBV) what had invested in INFI!
Daily analytics:
U.S. equity benchmarks ended Friday on a mixed note.
- The S&P 500 closed down -0.15% to 2,462
- The NASDAQ was down -0.7% to 6,357
- The Dow finished the week more or less flat at 21,789
The CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market; Friday traded at 12.12, up +4.94% …
- Thursday traded 11.88, down -0.69% after Wednesday traded at 11.63, down -4.91%, Tuesday traded at 12.23, up +20.73%, Monday was a holiday after last Friday traded at 10.13, down -4.34%
Welcome to another day of the sector’s roller coaster …
… The iShares Russell 2000 (IWM) indicated:
· Friday closed up +0.07%
· Thursday -0.25%
· Wednesday +0.20%
· Tuesday -0.95%
· Monday was a holiday
· Last Friday +0.54%
… The iShares NASDAQ Biotechnology (IBB) indicated:
· Friday closed down -0.34%
· Thursday +0.27%
· Wednesday +0.39%
· Tuesday -0.83%
· Monday was a holiday
· Last Friday +0.75%
The count - decliners versus gainers:
……. look at the differences in the spreads as decliners jump and %
· Friday’s decliners ranged from -0.15% <KITE -$0.27> to -8.19% <MDXG -$1.27> in 16 equities;
· Thursday’s decliners ranged from -0.21% <BLFS -$0.01> to -6.82% <VTGN -$0.12> in 11 equities;
· Wednesday’s decliners ranged from -0.28% <AXGN -$0.05> to -7.71% <CYTX -$0.03> in 22 equities;
· Tuesday’s decliners ranged from -0.04% <KITE -$0.07> to -20.26% <CLLS -$6.52> in 27 equities;
· Monday was a holiday
· Last Friday’s decliners ranged from -0.21% <ONCE -$0.17> to -3.70% <ADRO -$0.45> in 14 equities;
Versus
… Look at the percentage’s (%) and spreads …
· Thursday’s gainers ranged from +0.21% <KITE +$0.38> to +16.13% <FCSC +$0.40> in 28 equities;
· Wednesday’s gainers ranged from +0.08% <KITE +$0.14> to +28.13% <VSTM +$1.08> in 18 equities;
· Tuesday’s gainers ranged from +0.21% <CYTX +$0.01> to +19.95% <ISCO +$0.24> in 13 equities;
· Monday was a holiday
· Last Friday’s gainers ranged from +0.03% <KITE +$0.06> to +11.89% <CLLS +$3.42> in 27 equities;
Some of MY working trend lines or indications:
… The greatest volume to the downside: MDXG, KITE, JUNO, SGMO and BLCM
… Upside volume was weighted to: VSTM, NWBO, CYTX, ATHX and BSTG
… Biggest $ downside: BLUE, ONCE, MDXG, JUNO and BLCM
… Largest $ upside: CLLS, RGNX, FCSC, STML and VSTM
… Flat: VCEL, CAPR,NWBO, AXGN, AST, ONVO, RENE.L and CLBS
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
·
